Received Aug 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
they had been given Menveo (1 vial) to 2-month-old infants; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate age at vaccine administration in an unspecified number of patients who received Men ACWY-CRM NVS (Menveo) for prophylaxis. On an unknown date, the patient received Menveo. On an unknown date, an unknown time after receiving Menveo, the patient experienced inappropriate age at vaccine administration (Verbatim: they had been given Menveo (1 vial) to 2-month-old infants). The outcome of the inappropriate age at vaccine administration was not applicable. Additional Information: GSK Receipt Date: 19-AUG-2025 They just realize that Menveo product had 2 presentations, one that said that was for ages 10 through 55, and one that said for ages 2 months though 55, so they had been, reporter thought, given the adolescent product, the 10 through 55 years of age (Menveo 1 vial), probably to 2 month old infants which led to inappropriate age at vaccine administration. During the call, the healthcare professional informed that they had been given Menveo (1 vial) to 2 month old infants, however, they did not provide any patient details.